NKCx Histopathological outcome* within 12 months after cervix cytology in 2024
777 Skåne

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 38 6.0% 2 0.3% . . . . . . 1 0.2% 588 93.5% 629 100.0%
ASCUS 1349 52.8% 355 13.9% 54 2.1% 5 0.2% 1 0.0% 63 2.5% 728 28.5% 2555 100.0%
LSIL 739 41.4% 439 24.6% 119 6.7% 1 0.1% 1 0.1% 34 1.9% 452 25.3% 1785 100.0%
Atypical glandular cells/AGC 2 40.0% . . . . 3 60.0% . . . . . . 5 100.0%
Unclear atypia . . 1 100.0% . . . . . . . . . . 1 100.0%
ASC-H 28 17.8% 54 34.4% 60 38.2% 2 1.3% 4 2.5% 2 1.3% 7 4.5% 157 100.0%
HSIL 17 14.7% 11 9.5% 77 66.4% 2 1.7% 3 2.6% 2 1.7% 4 3.4% 116 100.0%
Suspected Adenocarcinom . . . . . . 1 50.0% . . . . 1 50.0% 2 100.0%
Squamous cell cancer . . . . 1 100.0% . . . . . . . . 1 100.0%
Totalt 2173 41.4% 862 16.4% 311 5.9% 14 0.3% 9 0.2% 102 1.9% 1780 33.9% 5251 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the
category Cancer:
M80703, M81403